is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics, Inc. Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
TG Therapeutics, Inc Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group